Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros

Banco de datos
Tipo del documento
Publication year range
1.
Calcif Tissue Int ; 115(2): 101-116, 2024 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-38833001

RESUMEN

Primary failure of eruption (PFE) is a rare disorder that is characterized by the inability of a molar tooth/teeth to erupt to the occlusal plane or to normally react to orthodontic force. This condition is related to hereditary factors and has been extensively researched over many years. However, the etiological mechanisms of pathogenesis are still not fully understood. Evidence from studies on PFE cases has shown that PFE patients may carry parathyroid hormone 1 receptor (PTH1R) gene mutations, and genetic detection can be used to diagnose PFE at an early stage. PTH1R variants can lead to altered protein structure, impaired protein function, and abnormal biological activities of the cells, which may ultimately impact the behavior of teeth, as observed in PFE. Dental follicle cells play a critical role in tooth eruption and root development and are regulated by parathyroid hormone-related peptide (PTHrP)-PTH1R signaling in their differentiation and other activities. PTHrP-PTH1R signaling also regulates the activity of osteoblasts, osteoclasts and odontoclasts during tooth development and eruption. When interference occurs in the PTHrP-PTH1R signaling pathway, the normal function of dental follicles and bone remodeling are impaired. This review provides an overview of PTH1R variants and their correlation with PFE, and highlights that a disruption of PTHrP-PTH1R signaling impairs the normal process of tooth development and eruption, thus providing insight into the underlying mechanisms related to PTH1R and its role in driving PFE.


Asunto(s)
Receptor de Hormona Paratiroídea Tipo 1 , Erupción Dental , Receptor de Hormona Paratiroídea Tipo 1/genética , Receptor de Hormona Paratiroídea Tipo 1/metabolismo , Humanos , Erupción Dental/genética , Erupción Dental/fisiología , Mutación , Diente no Erupcionado/genética , Animales , Enfermedades Dentales
2.
Shanghai Kou Qiang Yi Xue ; 31(6): 625-631, 2022 Dec.
Artículo en Zh | MEDLINE | ID: mdl-36970799

RESUMEN

PURPOSE: To study the expression level of semaphorin 4D (Sema4D) in bisphosphonate-related osteonecrosis of the jaw (BRONJ) and to explore its possible role in the occurrence of BRONJ. METHODS: BRONJ-like rat model was established by intraperitoneal injection of zoledronic acid assisted with tooth extraction. The maxillary specimens were extracted for imaging and histological examination, and bone marrow mononuclear cells(BMMs) and bone marrow mesenchymal stem cells(BMSCs) of each group were obtained in vitro for co-culture. Trap staining and counting were performed on monocytes after osteoclast induction. RAW264.7 cells were induced by osteoclast orientation under bisphosphonates(BPs) environment, and Sema4D expression was detected. Similarly, MC3T3-E1 cells and BMSCs were induced to osteogenic orientation in vitro, and the expression level of osteogenic and osteoclastic related genes ALP, Runx2, and RANKL was detected under the intervention of BPs, Sema4D and Sema4D antibody. Statistical analysis of the data was performed using GraphPad Prism 8.0 software. RESULTS: BRONJ-like rat model was successfully constructed. Two weeks after tooth extraction, the healing of the tooth extraction wound in the experimental group was significantly limited, and the tooth extraction wound was exposed. H-E staining results showed that regeneration of new bone in the extraction socket of the experimental group was significantly restricted, dead bone was formed, and the healing of the soft tissue was limited. The results of trap staining showed that the number of osteoclasts in the experimental group was significantly less than that in the control group. Micro-CT results showed that bone mineral density and bone volume fraction in the extraction socket of the experimental group were significantly lower than those of the control group. Immunohistochemical results showed that compared with the control group, the expression level of Sema4D in the experimental group was significantly increased. In vitro studies showed that compared with the control group, the osteoclast induction of BMMs in the experimental group was significantly lower than that in the control group. BMSCs in the experimental group significantly reduced the induction of osteoclasts. Osteoclastic induction experiments revealed that bisphosphonates could effectively inhibit the formation of osteoclasts, and the expression of Sema4D was significantly reduced. Osteogenic induction experiment found that Sema4D significantly reduced the expression of Runx2 and RANKL genes in osteoblasts, while the expression of ALP gene decreased and the expression of RANKL up-regulated after adding Sema4D antibody. CONCLUSIONS: BPs can interfere with normal bone healing time by up-regulating the expression of Sema4D in tissues, leading to coupling disorder between osteoclasts and osteoblasts with inhibition of the maturation of osteoclasts, thereby inhibiting the growth of osteoblasts. Differentiation and expression of related osteogenic factors mediate the development of BRONJ.


Asunto(s)
Osteonecrosis de los Maxilares Asociada a Difosfonatos , Semaforinas , Animales , Ratas , Osteonecrosis de los Maxilares Asociada a Difosfonatos/genética , Osteonecrosis de los Maxilares Asociada a Difosfonatos/metabolismo , Osteonecrosis de los Maxilares Asociada a Difosfonatos/patología , Subunidad alfa 1 del Factor de Unión al Sitio Principal/metabolismo , Difosfonatos/efectos adversos , Osteoclastos , Ácido Zoledrónico/efectos adversos , Semaforinas/genética , Semaforinas/metabolismo
3.
Shanghai Kou Qiang Yi Xue ; 24(2): 147-50, 2015 Apr.
Artículo en Zh | MEDLINE | ID: mdl-25938141

RESUMEN

PURPOSE: To prepare chitosan nanospheres for loading of BMP-2 and to evaluate its size, zeta potential, appearance, degradation and release characteristic in vitro, and then to investigate its feasibility as a carrier for sustained release of BMP-2. METHODS: The BMP-2 loaded chitosan nanospheres were prepared using ionic crosslinking method with tripolyphosphate (TPP) and chitosan. Transmission electron microscope was used to evaluate the morphological properties, and laser particle size analyzer was used to analyze particle size, Zeta potential and distribution. Lysozyme degradation experiment was performed to assess the biodegradation behavior. ELISA assay was used to determine the loading efficiency, encapsulation efficiency and in vitro drug release kinetics. The data was analyzed by SPSS 19.0 software package. RESULTS: The BMP-2 loaded chitosan nanospheres were spherical in shape, smooth on surface and uniform dispersion without aggregation. The mean diameter was 150.85 nm. The dispersion index was 0.37, and zeta potential was +35.42 mV. The average loading efficiency and encapsulation efficiency were (56.83 ± 2.26)% and (68.24 ± 3.83)%, respectively. Release experiment in vitro showed that the releasing property of BMP-2 loaded chitosan nanospheres was consistent with two-phase kinetic regulation and BMP-2 was controlled to release from the chitosan nanospheres over 30 days. CONCLUSIONS: The BMP-2 loaded chitosan nanospheres prepared by ionic crosslinking method are successfully prepared which show a good controlled release property. It provides the basis for further application in bone tissue engineering.


Asunto(s)
Proteína Morfogenética Ósea 2 , Quitosano , Sistemas de Liberación de Medicamentos , Nanosferas , Técnicas In Vitro , Tamaño de la Partícula , Farmacocinética , Polifosfatos
SELECCIÓN DE REFERENCIAS
Detalles de la búsqueda